BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12527933)

  • 21. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
    Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
    Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
    Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
    Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
    Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
    Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
    Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG
    Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
    Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
    Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
    Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM; Ni S; Tieu AT; Lieber A
    Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
    Dzojic H; Loskog A; Tötterman TH; Essand M
    Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
    Briones J; Timmerman J; Levy R
    Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
    Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
    Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer gene therapy using in vivo electroporation of Flt3-ligand.
    Shimao K; Takayama T; Enomoto K; Saito T; Nagai S; Miyazaki J; Ogawa K; Tahara H
    Int J Oncol; 2005 Aug; 27(2):457-63. PubMed ID: 16010428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model.
    Tanaka K; Towata S; Nakao K; Mizuguchi H; Hayakawa T; Niwa M; Ishii N; Nagayama Y
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):734-42. PubMed ID: 14974915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.
    Tsuchiyama T; Kaneko S; Nakamoto Y; Sakai Y; Honda M; Mukaida N; Kobayashi K
    Cancer Gene Ther; 2003 Apr; 10(4):260-9. PubMed ID: 12679798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for CD40-directed experimental therapy of human cancer.
    Tong AW; Stone MJ
    Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.